NantKwest Announces Studies in collaboration with the National Cancer Institute Demonstrating Enhanced Killing Activity of First-in-Class PD-L1 t-haNK Natural Killer Cell Across Every Cancer Cell Line Tested

NantKwest’s antibody-targeted NK cell line, haNK, which is engineered for increased antibody-dependent cell-mediated cytotoxicity and activation, showed increased resistance to hypoxic conditions as seen in suppressive tumor microenvironments NantKwest’s PD-L1 t-haNK...